Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3GSPR)

• Drug Name: GEM3PSCA Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM3GSPR

Molecule-Related Drug Atlas

Drug(s) Targeting Prostate stem cell antigen (PSCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anti-PSCA mab	DMJPZDC	Pancreatic cancer	2C10	Phase 2	[3]
BPX-601	DMV9QGW	Gastric adenocarcinoma	2B72	Phase 1/2	[4]
CAR-T cells targeting PSCA	DMU4G9J	Pancreatic cancer	2C10	Phase 1	[5]
CAR-T cells targeting PSCA	DMU4G9J	Pancreatic cancer	2C10	Phase 1	[6]
MB-105	DMVGTP6	Prostate cancer	2C82.0	Phase 1	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostate stem cell antigen (PSCA)	TT9T4AV	PSCA_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03927573) Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Gemoab.
• [3] Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71.
• [4] ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
• [5] ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
• [6] ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
• [7] Clinical pipeline report, company report or official report of Mustang Bio.